Ghent University Academic Bibliography

Your filters: cql: author="Kuhle, Jens" or (type any "bookEditor issueEditor" and editor="Kuhle, Jens")

Add to list
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Eva Kubala Havrdova, Tomas Kalincik, Izanne Roos, Suzanne Hodgkinson, Jeannette Lechner-Scott, et al.

(2026) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 97(1). p.50-58
Add to list
Effect of late-onset on multiple sclerosis phenotype and outcome : evidence from a multi-national registry

Amira Souissi, Francesco Patti, Tim Spelman, Clara Chisari, Amina Gargouri, Nevin John, Allan G. Kermode, Tomas Kalincik, Helmut Butzkueven, Seyed Aidin Sajedi, et al.

(2026) JOURNAL OF NEUROLOGY. 273(2).
Add to list
- Journal Article
- A1
- open access
Managing reactivation of multiple sclerosis during treatment with natalizumab

Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Anneke van der Walt, Helmut Butzkueven, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina, et al.

(2025) MULTIPLE SCLEROSIS JOURNAL. 32(1). p.121-133
Add to list
- Journal Article
- A2
- open access
Persistent progression independent of relapse activity in multiple sclerosis

Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Olga Skibina, Raed Alroughani, Jens Kuhle, Marc Girard, Pierre Grammond, et al.

(2025) BRAIN COMMUNICATIONS. 7(5).
Add to list
- Journal Article
- A1
- open access
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Axel Faes, Tomas Kalincik, Serkan Ozakbas, Riadh Gouider, Barbara Willekens, et al.

(2025) NPJ DIGITAL MEDICINE. 8(1).
Add to list
Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Dana Horakova, Bianca Weinstock-Guttman, Vahid Shaygannejad, Masoud Etemadifar, Raed Alroughani, et al.

(2025) JAMA NEUROLOGY. 82(6). p.614-625
Add to list
- Journal Article
- A1
- open access
Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Jessica Shipley, Heidi N. Beadnall, Paul G. Sanfilippo, Wei Zhen Yeh, Dana Horakova, Eva Kubala Havrdova, Pavel Hradilek, Tomas Kalincik, Izanne Roos, Alexandre Prat, et al.

(2025) JAMA NETWORK OPEN. 8(9).
Add to list
- Journal Article
- A2
- open access
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants : real-world evidence from MSBase

Tim Spelman, Sara Eichau, Raed Alroughani, Serkan Ozakbas, Samia J Khoury, Francesco Patti, Eva Kubala Havrdova, Cavit Boz, Murat Terzi, Jens Kuhle, et al.

(2024) MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL TRANSLATIONAL AND CLINICAL. 10(2). p.1-13
Add to list
- Journal Article
- A1
- open access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Suzanne Hodgkinson, Raed Alroughani, Sara Eichau Madueño, Cavit Boz, Anneke van der Walt, et al.

(2024) MULTIPLE SCLEROSIS JOURNAL. 30(9). p.1163-1175
Add to list
Routine CSF parameters as predictors of disease course in multiple sclerosis : an MSBase cohort study

Cathérine Dekeyser (UGent) , Matthias Hautekeete, Melissa Cambron, Vincent Van Pesch, Francesco Patti, Jens Kuhle, Samia Khoury, Jeanette Lechner Scott, Oliver Gerlach, Alessandra Lugaresi, et al.

(2024) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 95(11). p.1021-1031

Academic Bibliography

Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Effect of late-onset on multiple sclerosis phenotype and outcome : evidence from a multi-national registry

Managing reactivation of multiple sclerosis during treatment with natalizumab

Persistent progression independent of relapse activity in multiple sclerosis

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants : real-world evidence from MSBase

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Routine CSF parameters as predictors of disease course in multiple sclerosis : an MSBase cohort study

Contents

Support

Contact